Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction

Annals of Allergy, Asthma and Immunology

Volumn 93, Issue 6, 2004, Pages 562-567

  Purohit, Ashok ^a,b   N'Gom, A Severin ^a,b   Deslandes, Bruno ^c   Pauli, Gabrielle ^a,b   Frossard, Nelly ^a,b,d  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c SANOFI   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; FEXOFENADINE; HISTAMINE; HISTAMINE H1 RECEPTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SKIN TEST; URTICARIA;

EID: 10344228769     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61264-1     Document Type: Article

References (44)

1. Campoli-Richards DM, Buckley MM, Fitton A. Cetirizine: a review of its pharmacological properties and clinical potential in allergic rhinitis, pollen induced asthma and chronic urticaria. Drugs. 1990;40:762-781.
2. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol. 1996;97:617-626.
3. Bernstein DI, Schoenwetter WF, Nathan RA. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79: 443-448.
4. Day JH, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. J Allergy Clin Immunol. 1997;79:533-540.
5. 1-receptor antagonist, in the treatment of fall allergies. Allergy Asthma Proc. 1998;19:135-141.
6. Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc. 1999;20:193-198.
7. Howarth PH, Stern MA, Roi L, Reynolds R, Bousquet J. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104:927-933.
8. Meltzer EO, Casale TB, Nathan RA, Thompson AK. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1999;83:311-317.
9. van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000;30:891-899.
10. Juhlin L, Arendt C. Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. J Dermatol. 1988;119:67-72.
11. Breneman D, Bronsky EA, Bruce S, et al. Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial. J Am Acad Dermatol. 1995;33:192-198.
12. Paul E, Berth-Jones J, Stern M. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treatment. 1998;9:143-149.
13. Markham A, Wagstaff AJ. Fexofenadine. Drugs. 1998;55: 269-274.
14. Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999;104:1071-1078.
15. Kalivas J, Breneman D, Tharp M, Bruce S, Bigby M. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol. 1990;86:1014-1018.
16. Spencer CM, Faulds D, Peters DH. Cetirizine: a reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders. Drugs. 1993;46:1055-1080.
17. 14C-cetirizine in humans Ann Allergy. 1987;59:31-34.
18. Nicolas JM, Whomsley R, Collart P, Roba J. In vitro inhibition of human liver drug metabolizing enzymes by second-generation antihistamines. Chem Biol Interact. 1999;123: 63-79.
19. Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy. 1999;29(Suppl):116-124.
20. 1-receptor antagonists. J Allergy Clin Immunol. 2001;107:526-530.
21. Baltes E, Coupez R, Brolwers L, Gobert J. Gas chromatographic method for the determination of cetirizine in plasma. J Chromatogr. 1988;430:149-155.
22. 1-receptor antagonists in skin and serum. J Allergy Clin Immunol. 1995; 95:759-764.
23. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther. 1998;64:612-621.
24. Simons FE, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J Allergy Clin Immunol. 1990;86: 540-547.
25. 1-blockade effect of fexofenadine. Ann Allergy Asthma Immunol. 1997;79:530-532.
26. Grant JA, Danielson L, Rihoux JP, Devos C. A double-blind, single dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy. 1999;54: 700-707.
27. 1 profile of second generation antihistamines. Allergy. 2000;55:40-45.
28. Walsh GM, Annunziato L, Frossard N, et al. New insights into the second generation antihistamines. Drugs. 2001;61: 207-236.
29. Frossard N. Pharmacodynamics of antihistamines: from concept to reality. Clin Exp Allergy Rev. 2003;3:87-89.
30. Braunstein G, Malaquin F, Fajac I, Melac M, Frossard N. Inhibition of histamine-inducted nasal obstruction by cetirizine in allergic rhinitis. Br J Clin Pharmacol. 1992;33:445-448.
31. Frossard N, Lacronique J, Mélac M, Pauli G. Onset of action in the nasal antihistamine effect of cetirizine and loratadine in subjects with allergic rhinitis. Allergy. 1997;52:205-209.
32. Frossard N, Benabdesselam O, Mélac M, Glasser N, Lacronique J, Pauli G. Nasal effect of cetirizine and loratadine at 24 hours in patients with allergic rhinitis. Am J Ther. 1998;5:307-311.
33. Allocco FT, Votypka V, deTineo M, Naclerio RM, Baroody FM. Effects of fexofenadine on the early response to nasal allergen challenge. Ann Allergy Asthma Immunol. 2002;89: 578-584.
34. Berkowitz RB, Woodworth GG, Lutz C, et al. Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. Ann Allergy Asthma Immunol. 2002;89:38-45.
35. Frossard N, Melac M, Benabdesselam O, Pauli G. Consistency of the efficacy of cetirizine and ebastine on skin reactivity. Ann Allergy Asthma Immunol. 1998;80:61-65.
36. Purohit A, Duvernelle C, Mélac M, Pauli G, Frossard N. Twenty-four hour activity of cetirizine and fexofenadine in the skin. Ann Allergy Asthma Immunol. 2001;86:387-392.
37. Simons FE, Norman AS, Xiaochen G, Simons KJ. Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol. 2002;110:777-783.
38. EMEA Committee for Proprietary Medicinal Products (CPMP). CPMP/EWP/482/99 points to consider on switching between superiority and non-inferiority. Available at: http:// www.emea.eu.int/pdfs/human/ewp/048299en.pdf. Accessed September 11, 2004.
39. Demoly P, Bousquet J, Manderscheid JC, Dreborg S, Dhivert H, Michel FB. Precision of skin prick and puncture tests with nine methods. J Allergy Clin Immunol. 1991;88:758-762.
40. Purohit A, Duvernelle C, Melac M, Benabdesselam O, Pauli G, Frossard N. Consistency and efficacy of cetirizine (10 mg) versus ebastine (20 mg) at 4 h on skin reactivity. Eur J Clin Pharmacol. 1999;55:589-592.
41. Kaliner MA, White MV, Economides A, et al. Relative potency of fexofenadine HCl 180 mg, loratadine 10 mg, and placebo using a skin test model of wheal-and-flare suppression. Ann Allergy Asthma Immunol. 2003;90:629-634.
42. Day JH, Briscoe M, Rafeiro E, Chapman D, Kramer B. Comparative onset of action and symptom relief with cetirizine, loratadine or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol. 2001;87:474-481.
43. 1-receptor antagonists: safety issues. Ann Allergy Asthma Immunol. 1999;83:481-488.
44. Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy. 1999;29:163-170.